Overview

This trial is active, not recruiting.

Conditions hematologic diseases, healthy volunteers
Treatment isolation of genomic dna
Sponsor The University of Texas Health Science Center at San Antonio
Collaborator VA Office of Research and Development
Start date March 2005
End date August 2017
Trial size 1000 participants
Trial identifier NCT00223483, HSC20040268H

Summary

This research study goal is to analyze the plasma and the cells that make up part of the immune system. We want to learn how the plasma and cells work. These may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Time perspective prospective

Primary Outcomes

Measure
Repository collection of plasma and serum for future analysis.
time frame: 12 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Must be able to give blood - Must be able to give informed consent - Signed, written informed consent Exclusion Criteria: - Individuals with a history severe anemia, inadequate venous access, severe blood or coagulation disorders. - Pregnant women are excluded because it is a unique immunotolerant state and will alter the profile of immunomodulatory molecules.

Additional Information

Official title Identification and Analysis of Immunomodulatory Molecules From Leukocytes in Patients With Hematologic Disorders and Healthy Volunteers
Description This research study goal is to analyze the plasma and the cells that make up part of the immune system. These cells, called white cells or leukocytes, are present in blood. We want to learn how these cells work to prevent infection and how they respond after an infection occurs. We also want to study certain molecules present on the plasma, on or in these cells, and the genetic material that allows these molecules to be made. These molecules may influence why one person will develop an infection and another will not, or why one person develops severe symptoms of a disease while others remain without symptoms. This study may increase our understanding of a variety of diseases including infections such as HIV, allergic diseases such as asthma, joint diseases such as rheumatoid arthritis, certain cancers, and the rejection process that sometimes occurs after transplantation of an organ.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by The University of Texas Health Science Center at San Antonio.